Biblio
"Allogeneic blood or marrow transplant with non-myeloablative conditioning and high dose cyclophosphamide-based graft-versus-host disease prophylaxis for secondary central nervous system lymphoma". Transplant Cell Ther. 2021.
Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. Blood Adv. 2022.
Donor T-cell DNMT3a regulates alloreactivity in murine models of hematopoietic stem cell transplantation. J Clin Invest. 2022.
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770-1779.
How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Blood. 2019;134(21):1802-1810.
. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.
Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. J Clin Invest. 2019;130.
. Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose posttransplantation cyclophosphamide. Transplant Cell Ther. 2021.
Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplant in Acute Myeloid Leukemia. Transplant Cell Ther. 2021.
Severe cytokine release syndrome after haploidentical peripheral blood transplantation. Biol Blood Marrow Transplant. 2019.
Signatures of immune dysfunction predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022.